Insulin Receptor

Introduction

The insulin receptor is a fundamental protein embedded in the cell membrane, playing a pivotal role in the body’s metabolic regulation. Its primary function is to bind insulin, a hormone crucial for managing glucose levels in the blood. This binding initiates a complex intracellular signaling cascade that enables cells to absorb glucose, synthesize glycogen, and carry out other vital metabolic processes. Proper functioning of the insulin receptor is essential for maintaining glucose homeostasis and overall metabolic health.

Biological Basis

The insulin receptor (INSR) is a transmembrane tyrosine kinase receptor. Upon insulin binding, the receptor undergoes a conformational change that activates its intrinsic tyrosine kinase activity, leading to the phosphorylation of various intracellular proteins. This cascade ultimately facilitates glucose uptake into cells, particularly in muscle and fat tissues, and regulates glucose production in the liver. Genetic factors can influence the abundance of proteins, including the insulin receptor, in human blood plasma.^[1] Studies have identified genetic variants known as protein quantitative trait loci (pQTLs) that are associated with variations in circulating levels of numerous proteins.^[2]Specifically, the insulin receptor (INSR) has been identified as a protein whose plasma levels are influenced by a trans-pQTL, meaning a genetic variant located on a different chromosome or far from the INSR gene itself.^[2]

Clinical Relevance

Dysregulation of insulin receptor function or expression is a hallmark of several significant metabolic disorders. Conditions such as type 2 diabetes, insulin resistance, and metabolic syndrome are characterized by impaired insulin signaling, often stemming from issues with the insulin receptor or its downstream pathways. Measuring insulin receptor levels or assessing its functional state could potentially serve as a biomarker for disease risk, progression, or therapeutic response. Understanding the genetic influences on insulin receptor levels provides insights into the genetic susceptibility to these diseases. Research into pQTLs helps bridge the gap between genetic risk factors and disease outcomes by examining their impact on the proteome.^[2]Such genetic insights can be instrumental in validating potential drug targets and elucidating disease mechanisms.^[2]

Social Importance

Given the global epidemic of type 2 diabetes and related metabolic disorders, understanding the mechanisms governing insulin receptor function holds immense social importance. These diseases contribute substantially to healthcare burdens and reduce quality of life for millions. Genetic studies that identify factors influencing insulin receptor levels can lead to more precise diagnostics, improved risk stratification, and the development of targeted therapies. By unraveling the genetic architecture underlying protein abundance, including that of the insulin receptor, researchers can accelerate drug discovery and optimize treatment strategies, ultimately aiming to mitigate the societal impact of these prevalent chronic conditions.^[2]

Methodological and Statistical Constraints

The interpretation of findings related to insulin receptor is influenced by various methodological and statistical challenges inherent in large-scale genetic association studies. Replication rates for identified loci can vary significantly across different Genome-Wide Association Study (GWAS) methods, underscoring the need for careful validation. For instance, some methods, such as REGENIE, have been shown to produce inflated test statistics in datasets with high levels of relatedness, while linear regression models may lack robustness when population structure is present.^[3] The choice of GWAS method for replication analysis can also impact the detected number of replicated loci, suggesting that findings may be somewhat method-dependent.^[3] To mitigate type I error and improve statistical power, repeat adjustments and stringent significance thresholds, such as Bonferroni-adjusted levels, are often implemented in discovery analyses.^[4] Challenges in statistical calibration further limit the confidence in some findings. While certain advanced methods, like Quickdraws, have demonstrated calibration across various simulation conditions and for low-prevalence binary traits, ensuring a low rate of false-positive associations, other methods may struggle.^[3]For example, Quickdraws exhibited higher variance in false-positive rate (FPR) estimates in simulations involving nonhomogeneous ancestry, which could be attributed to increased noise in the estimated effective sample size derived from fewer unrelated homogeneous individuals.^[3] Although some studies report low genomic inflation and thus forgo inflation correction.^[2] the overall robustness and reliability of associations can be sensitive to the underlying population structure and relatedness within cohorts.

Generalizability and Phenotypic Characterization

A significant limitation in understanding insulin receptor genetics is the generalizability of findings, primarily due to the demographic characteristics of study cohorts. Many large-scale studies predominantly consist of participants of European descent, such as those focusing on European or British ancestry subgroups within the UK Biobank.^[3]This demographic skew necessitates replication and validation in ethnically diverse populations, particularly for findings related to insulin receptor, to ensure their broader applicability and to identify potential population-specific genetic architectures.^[1] Efforts to account for non-genetic racial effects through residualization on race, in addition to genetic ancestry principal components, highlight the recognized importance of these factors.^[4]Beyond population representation, the nature of the protein technologies themselves presents limitations. Assays designed to maximize discovery by generating large libraries of affinity reagents often rely on the preserved shape of the target protein. This reliance means they might miss genetic effects specific to particular isoforms of the insulin receptor, potentially overlooking crucial biological details.^[1] Furthermore, the semi-quantitative nature of these assays can pose challenges for advanced analytical approaches, such as Mendelian randomization studies, which typically require precise quantitative measures for robust risk estimates.^[1] Extensive pre-processing steps, including log-transformation, scaling, and residualization for factors like age, sex, batch, and principal components of ancestry, are routinely applied to normalize protein levels and account for technical variability, but these steps also reflect the complexity and potential for uncaptured variation in the raw phenotypic data.^[5]

Unaccounted Variability and Knowledge Gaps

Despite comprehensive efforts to adjust for known confounders, a degree of unexplained variability in insulin receptor levels often remains, contributing to the challenge of fully elucidating its genetic architecture. While studies meticulously control for a wide array of covariates, including age, sex, smoking status, body mass index, alcohol consumption, education, income, and even technical factors like collection site, batch, and time between blood sampling and protein , the complex interplay of these environmental and lifestyle factors, and their potential gene-environment interactions, may not be fully captured.^[3]Furthermore, technical confounders, such as variability introduced by cell hemolysis, necessitate statistical adjustment, indicating their significant impact on protein quantification.^[2]The concept of missing heritability also applies to insulin receptor, as SNP-based heritability estimates do not always account for the total genetic variance. In some cases, proteins with very low heritability estimates are excluded from analyses because their heritability cannot be reliably determined by existing models.^[4]This indicates that a portion of the genetic contribution to insulin receptor levels remains unexplained. Moreover, specific knowledge gaps persist regarding the precise molecular mechanisms. Current protein technologies may not differentiate between various protein isoforms, potentially obscuring genetic effects that influence specific receptor forms with distinct functions.^[1]The semi-quantitative nature of available data also fundamentally limits the application of certain causal inference methods, such as Mendelian randomization, thereby impeding a deeper understanding of the causal links between genetic variants, insulin receptor levels, and related health outcomes.^[1]

Variants

Genetic variations play a crucial role in influencing protein levels and cellular functions, with direct and indirect implications for insulin receptor activity and overall metabolic health. Several variants, particularly those within theABOblood group locus, exhibit widespread associations with circulating proteins and disease endpoints, including diabetes. For instance, theABO locus, encompassing variants like rs532436 , rs507666 , and rs2519093 , has been strongly associated with diabetes and INSR-mediated insulin signaling, suggesting a direct link to glucose metabolism.^[6]This pleiotropic gene, responsible for determining blood groups, influences the levels of numerous proteins, including the insulin receptor itself, and has been linked to conditions such as coronary artery disease, venous thromboembolism, pancreatic cancer, and susceptibility to infectious diseases.^[6] Another variant, rs651007 , also located near the ABO locus, is associated with plasma P-selectin (SELP) levels, a marker involved in inflammation and vascular processes, and has been linked to blood pressure regulation and angiotensin converting enzyme activity.^[6]The insulin receptor gene,INSR, and its variant rs1799815 , are central to insulin signaling, and variations affecting its expression or function can directly impact insulin sensitivity and glucose uptake, making its critical for understanding metabolic disorders.

Other variants influence a range of plasma proteins and cell adhesion molecules, which can indirectly affect insulin signaling pathways. The variantrs704 in the VTN and SARM1region, for example, is strongly associated with circulating levels of vitronectin, an adhesive glycoprotein involved in cell adhesion, migration, and hemostasis.^[7]Vitronectin’s role in extracellular matrix interactions can influence cellular responses and potentially impact the microenvironment where insulin signaling occurs. Similarly, variantsrs760462 and rs760459 within the ITGB2gene, which encodes a subunit of integrin adhesion receptors, are crucial for leukocyte function and inflammation. Given that chronic inflammation is a known contributor to insulin resistance, variations inITGB2could modulate inflammatory responses that impact insulin receptor sensitivity. Furthermore,rs1801689 in APOH (Apolipoprotein H), involved in coagulation and lipid metabolism, and rs112635299 located between SERPINA2 and SERPINA1 (which encodes alpha-1 antitrypsin, a key protease inhibitor), can influence protein homeostasis and inflammatory pathways, thereby having downstream effects on metabolic health.

Beyond these, variants in genes like ATXN2 and SLFN12L, along with specific YRNA elements, contribute to the intricate network of genetic influences on cellular processes. The variant rs35350651 in _ATXN2(Ataxin 2) is associated with RNA metabolism and protein synthesis, functions that are fundamental to cellular health and metabolic regulation. Disruptions in these basic cellular mechanisms can indirectly impair cell function and stress responses, potentially affecting insulin sensitivity. Similarly,rs11658693 in SLFN12L, part of a gene family involved in cell growth and differentiation, may play a role in regulatory pathways that, when altered, could subtly influence cellular responses to insulin. The Y_RNA variants, includingrs368419571 and rs12598978 , represent small non-coding RNAs that participate in RNA processing and stress responses, illustrating how even subtle genetic differences in these regulatory elements can contribute to the complex interplay of factors affecting overall cellular physiology and metabolic balance.

Key Variants

RS ID	Gene	Related Traits
rs532436 rs507666 rs2519093	ABO	myocardial infarction E-selectin amount intercellular adhesion molecule 1 brain attribute blood protein amount
rs651007	ABO - Y_RNA	iron biomarker , ferritin hematocrit E-selectin amount low density lipoprotein cholesterol factor VIII
rs1801689	APOH	coronary artery disease low density lipoprotein cholesterol platelet count serum alanine aminotransferase amount apolipoprotein B
rs704	VTN, SARM1	blood protein amount heel bone mineral density tumor necrosis factor receptor superfamily member 11B amount low density lipoprotein cholesterol protein
rs35350651	ATXN2	blood protein amount stroke, type 2 diabetes mellitus, coronary artery disease primary biliary cirrhosis triglycerides:totallipids ratio, low density lipoprotein cholesterol triglycerides:totallipids ratio, intermediate density lipoprotein
rs1799815	INSR	waist-hip ratio insulin BMI-adjusted waist-hip ratio BMI-adjusted waist circumference insulin receptor
rs368419571 rs12598978	Y_RNA - Y_RNA	insulin receptor
rs760462 rs760459	ITGB2	blood protein amount ADGRE5/ITGB2 protein level ratio in blood ITGB1/ITGB2 protein level ratio in blood level of tumor necrosis factor receptor superfamily member 10C in blood insulin-like growth factor 1 receptor amount
rs112635299	SERPINA2 - SERPINA1	forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator coronary artery disease BMI-adjusted waist circumference C-reactive protein
rs11658693	SLFN12L	insulin receptor

Definition and Biological Significance of the Insulin Receptor

The insulin receptor (INSR) is a crucial transmembrane glycoprotein that mediates the pleiotropic effects of insulin, a key hormone in metabolic regulation. Its primary function involves binding insulin, which initiates a signaling cascade vital for glucose homeostasis, including the cellular uptake, utilization, and storage of glucose.^[2] As a quantitative trait, plasma INSR levels can serve as a measurable indicator reflecting an individual’s metabolic status and genetic underpinnings. Variations in the expression or function of INSRare directly implicated in metabolic disorders, particularly diabetes, highlighting its significance in understanding disease pathogenesis and identifying potential therapeutic targets.^[2]

Approaches and Operational Definitions

The quantification of insulin receptor levels, especially within large-scale proteo-genomic studies, typically employs high-throughput proteomics platforms. These advanced techniques often utilize aptamers, such as those found in SOMAscan technology, to specifically bind and measure the concentration of proteins in biological samples like blood plasma or serum.^{[2], [5]} Operational definitions for INSRin genetic association studies involve a multi-step data processing pipeline. Initially, raw protein abundance data are commonly natural log-transformed and then statistically adjusted via linear regression for covariates such as age, sex, body mass index, and diabetes status.^{[2], [4], [5]} Further adjustments may incorporate principal components derived from both genetic and proteomics data to account for population stratification and technical variability, with the resulting protein residuals often undergoing rank-inverse normalization before being used as phenotypes for genetic association testing.^{[2], [5]}

Classification and Terminology in Proteo-Genomic Studies

In the field of proteo-genomics, specific terminology is used to classify the genetic determinants of protein levels. “Protein quantitative trait loci” (pQTLs) refer to genomic regions associated with variations in protein abundance.^{[2], [5]} These pQTLs are further categorized based on their genomic proximity to the gene encoding the protein: “cis-associations” occur when the associated genetic variant is located within a defined distance, typically 10 megabases (Mb), of the protein-coding gene, while “trans-associations” describe variants located further away.^[2]Within a pQTL locus, the single nucleotide polymorphism (SNP) exhibiting the strongest statistical association is termed a “sentinel SNP,” and the corresponding protein is referred to as a “sentinel probe”.^[2]To standardize the interpretation of genetic findings in a clinical context, disease traits and drug indications are often mapped to hierarchical classification systems like the Medical Dictionary for Regulatory Activities (MedDRA), which facilitates consistent communication and analysis of disease-related genetic associations.^[5]

Criteria for Association and Clinical Interpretation

The identification of significant associations between genetic variants and INSR levels relies on stringent statistical criteria in genome-wide association studies (GWAS). To account for the massive number of tests performed, highly conservative p-value thresholds are applied, such as a genome- and proteome-wide significance level of Po8.72 × 10−11.^[2] For replication studies or analyses focusing on specific loci, Bonferroni-corrected significance thresholds, such as Po1.08 × 10−4 or Po0.05/462, are employed to ensure the robustness of findings.^[2] These rigorous criteria help to minimize false-positive results and enhance the reliability of detected associations. The plasma levels of proteins like INSR, when linked to genetic variants through pQTLs, serve as critical biomarkers that bridge genetic risk factors with observable disease endpoints.^[2] Such connections are instrumental for validating potential drug targets and for investigating dose-response relationships for therapeutic compounds, thereby advancing precision medicine.^[2]

The Insulin Receptor: Structure, Function, and Signaling

The insulin receptor (INSR) is a pivotal transmembrane glycoprotein that plays a central role in mediating the diverse biological actions of insulin. As a receptor,INSRis primarily responsible for binding insulin, a key hormone, initiating a complex intracellular signaling cascade upon ligand binding. This process is fundamental to various cellular functions, including glucose uptake, metabolism, and cell growth. TheINSR exists as both a membrane-bound form and soluble domains of the receptor, which can be detected in plasma using advanced proteomic assays.^[5]

Insulin Signaling and Metabolic Regulation

The activation of INSRinitiates a complex molecular and cellular signaling pathway crucial for maintaining metabolic homeostasis throughout the body. Upon insulin binding,INSRundergoes autophosphorylation, recruiting and activating various downstream signaling molecules that regulate glucose metabolism, lipid synthesis, and protein synthesis. This intricate regulatory network ensures that cells efficiently absorb nutrients from the bloodstream, preventing hyperglycemia and other metabolic imbalances. Disruptions in this pathway can lead to widespread systemic consequences, profoundly affecting energy balance and overall physiological function.

Genetic and Epigenetic Influences on Insulin Receptor Levels

The abundance of the insulin receptor protein is subject to complex genetic and epigenetic regulation, influencing its expression and circulating levels. Studies have identified genetic variations, including quantitative trait loci (pQTLs), that significantly impact the plasma concentrations of various proteins, including the insulin receptor.^{[1], [8], [9], [10]} Notably, INSR protein levels have been identified as a “trans-association,” meaning its circulating levels are influenced by genetic variants located far from the INSR gene itself, such as those within the ABO locus.^[2] These genetic mechanisms, alongside potential epigenetic modifications that influence gene expression patterns, dictate INSRprotein stability and ultimately affect the cellular capacity to respond to insulin, contributing to individual variability in metabolic responses.^[11]

Insulin Receptor Dysregulation and Pathophysiological Processes

Dysregulation of INSRfunction or expression is a hallmark of several pathophysiological processes, particularly those involving metabolic disorders. Impaired insulin signaling, often due to reducedINSRsensitivity or decreased receptor numbers, directly contributes to conditions like type 2 diabetes, where cells fail to adequately respond to insulin’s metabolic signals. Research highlights the involvement ofINSR-mediated insulin signaling in the association between theABO blood group locus and diabetes, underscoring the systemic consequences of genetic variations on metabolic health.^[2]Understanding these disease mechanisms and homeostatic disruptions is crucial for identifying therapeutic targets and developing strategies to restore proper insulin action and mitigate disease progression.

Insulin Receptor Signaling and Cellular Response

The insulin receptor,INSR, plays a pivotal role in mediating the cellular responses to insulin, initiating a cascade of intracellular signaling events fundamental for metabolic regulation. Upon insulin binding,INSR, a receptor tyrosine kinase, undergoes autophosphorylation and activates downstream signaling molecules. This activation is crucial for regulating cellular processes such as glucose uptake, utilization, and storage, primarily in insulin-sensitive tissues.^[2]The proper functioning of this signaling pathway ensures that cells respond appropriately to circulating insulin levels, maintaining metabolic homeostasis throughout the body.

Genetic and Epigenetic Regulation of INSR Expression

The abundance and activity of the INSR protein are subject to intricate genetic and regulatory control, impacting its functional capacity. Genetic variations, identified as protein quantitative trait loci (pQTLs), have been shown to influence the levels of various proteins, including those involved in critical signaling pathways.^[9] Studies have specifically linked genetic loci, such as the ABO locus, to influencing INSR levels and, consequently, INSR-mediated insulin signaling.^[2] Furthermore, regulatory mechanisms like transcription factor binding site patterns can link genetic risk loci for diseases such as diabetes to underlying molecular mechanisms, suggesting transcriptional control plays a significant role in INSR expression and its physiological relevance.^[12]

Metabolic Integration and Energy Homeostasis

INSRsignaling is central to the integration of metabolic pathways, orchestrating energy metabolism, biosynthesis, and catabolism across various tissues. Its activation leads to widespread metabolic regulation, influencing glucose and lipid metabolism to ensure adequate energy supply and storage. Genetic variations impacting metabolic phenotypes highlight the intricate control mechanisms governing these processes, where changes inINSR function can alter metabolic flux and contribute to systemic metabolic dysregulation.^[13] Effective INSR function is therefore critical for maintaining stable glycemic control and overall energy balance within the body .

Systems-Level Pathway Crosstalk and Network Interactions

The INSRpathway does not operate in isolation but is intricately integrated into a broader network of cellular and systemic interactions, demonstrating significant pathway crosstalk. This systems-level integration is evident in the complex genome-proteome-disease networks, where genetic influences on protein levels, includingINSR, connect to various disease endpoints.^[2] For instance, the association between the ABO locus and diabetes is suggested to involve INSR-mediated insulin signaling, illustrating how genetic factors can modulate disease risk through specific protein pathways.^[2] Such network interactions underscore the hierarchical regulation and emergent properties that arise from the interplay of multiple biological pathways, essential for maintaining physiological robustness.

Disease Relevance and Therapeutic Targeting

Dysregulation of INSR pathways is a key mechanism underlying various metabolic diseases, most notably diabetes. Alterations in INSRlevels or signaling efficiency can lead to impaired glucose metabolism and insulin resistance, contributing to disease pathogenesis.^[2]Understanding these disease-relevant mechanisms is crucial for identifying potential therapeutic targets. Human genetics studies, by connecting genetic risk to disease endpoints through the proteome, provide a powerful approach for validating such targets.^[14] The ability to measure and characterize INSRlevels and function thus offers critical insights into disease development and informs strategies for pharmacological intervention.

Prognostic Value and Risk Stratification

of plasma proteins, including the insulin receptor, holds significant potential for predicting disease outcomes and stratifying individuals based on risk. Large-scale proteomic studies, often employing techniques like the SOMAscan assay, identify genetic variants (protein quantitative trait loci, or pQTLs) that influence circulating protein levels.^[2]By leveraging Mendelian randomization, researchers can assess the causal effect of changes in protein biomarker levels on disease risk, providing insights into long-term implications and disease progression.^[5] This approach facilitates the identification of high-risk individuals for various metabolic conditions, allowing for the development of personalized prevention strategies and more precise prognostication of patient trajectories.

Diagnostic Utility and Treatment Selection

The clinical utility of measuring plasma proteins extends to diagnostic applications and guiding treatment choices. Proteomic platforms enable the identification of specific protein profiles that may serve as early diagnostic markers or refine risk assessments for conditions associated with insulin dysregulation.^[2] Furthermore, the aptamers used in some proteomic assays can function as intermediate readouts to evaluate drug responses and optimize the efficacy of therapeutic compounds, providing a direct link between protein levels and pharmacological intervention.^[2] Identifying protein targets with human genetic support, as demonstrated through extensive proteo-genomic mapping, increases the likelihood of successful drug development and supports the selection of targeted treatments for improved patient care.^[5]

Comorbidities and Associated Conditions

Plasma proteome analysis offers a comprehensive view of how insulin receptor function may be implicated in various comorbidities and complex disease phenotypes. Studies analyzing the plasma proteome across diverse populations, including Black adults, have provided novel insights into the genetic architecture connecting proteins to cardiovascular disease and other conditions.^[4]By examining the associations between insulin receptor levels and other circulating proteins or clinical traits, researchers can uncover overlapping phenotypes and better understand the systemic complications linked to insulin signaling pathways. This integrated approach can inform more holistic management strategies for patients presenting with multiple related conditions.

Frequently Asked Questions About Insulin Receptor

These questions address the most important and specific aspects of insulin receptor based on current genetic research.

---

1. Can a blood test tell me if I’m at high risk for diabetes?

Yes, measuring certain proteins in your blood, like the insulin receptor, could potentially act as a biomarker. Genetic factors influence the levels and function of this receptor, and understanding these can provide insights into your risk for conditions like type 2 diabetes and metabolic syndrome. This information can help your doctor assess your metabolic health.

2. My family has diabetes; am I destined to get it too?

While genetics play a significant role in your susceptibility, you’re not necessarily destined to develop diabetes. Genetic variations, including those affecting the insulin receptor (INSR), can increase your risk, but lifestyle choices like diet and exercise are also incredibly important in managing and potentially mitigating that risk over your lifetime.

3. Could knowing my ‘insulin receptor’ status help my doctor treat me?

Yes, understanding your insulin receptor status could be very beneficial. Measuring its levels or how well it functions can act as a biomarker, helping your doctor achieve more precise diagnostics. This information can guide them in tailoring treatment strategies specifically for you and monitoring how effectively a therapy is working.

4. Why do some people eat anything and not get insulin resistance?

Everyone’s metabolism is unique, partly due to genetic differences. Some individuals have genetic variants, known as pQTLs, that influence the abundance or efficiency of their insulin receptors. These genetic factors can make their bodies naturally better at managing glucose and less prone to developing insulin resistance, even with less-than-ideal diets.

5. Does my ethnic background change my risk for insulin problems?

Yes, your ethnic background can influence your genetic risk for insulin problems. The genetic architecture, including factors affecting the insulin receptor, can vary across different populations. This means that genetic risk factors or the effectiveness of certain treatments might differ, highlighting the importance of research in diverse groups.

6. Can exercise overcome bad genetics if my insulin receptor isn’t great?

Exercise and a healthy lifestyle are powerful tools. While genetic variations, such as those impacting your insulin receptor (INSR), can predispose you to metabolic issues, consistent lifestyle efforts can often significantly mitigate or delay the onset of these conditions. You can definitely influence your health outcomes, even with a genetic predisposition.

7. Why do I struggle with blood sugar even when I try really hard?

It can be incredibly frustrating, and sometimes underlying genetic factors are at play. Your body’s ability to manage blood sugar is heavily influenced by the function of your insulin receptor, which can be affected by specific genetic variants. These differences can make it inherently more challenging for some individuals to maintain stable blood sugar levels despite their best efforts.

8. Are these ‘insulin receptor’ tests accurate for everyone?

The accuracy and generalizability of these types of tests can vary. Much of the research identifying genetic influences on proteins like the insulin receptor has predominantly focused on populations of European descent. This means findings might not always be as robust or applicable to individuals from other ethnic backgrounds, and the assays themselves can have limitations.

9. Could a new medicine target my insulin receptor specifically?

Yes, that’s a major focus of current research! Scientists are using insights from genetics, including how variants affect proteins like the insulin receptor, to identify and validate new drug targets. The ultimate goal is to develop more precise and targeted therapies that can specifically address dysregulation of the insulin receptor to treat metabolic diseases more effectively.

10. If I have insulin issues, will my kids definitely have them?

Not necessarily, but your children might have an increased genetic susceptibility. Conditions like insulin resistance and type 2 diabetes often involve a complex interplay of multiple genes, includingINSR, and environmental factors. While they may inherit some genetic predispositions from you, it doesn’t guarantee they will develop the conditions, and their own lifestyle choices will play a significant role.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Pietzner M, et al. Mapping the proteo-genomic convergence of human diseases. Science. 2021 Oct 15;374(6565):eabj1541.

[2] Suhre K, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 2017 Feb 27;8:14357.

[3] Loya H. A scalable variational inference approach for increased mixed-model association power. Nat Genet. 2025 Feb;57:461–468.

[4] Katz DH, et al. Whole Genome Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into Cardiovascular Disease. Circulation. 2021 Feb 1;143(5):454-473.

[5] Sun BB, et al. Genomic atlas of the human plasma proteome. Nature. 2018 Jun;558(7711):596–601.

[6] Suhre, K., et al. “Connecting genetic risk to disease end points through the human blood plasma proteome.”Nat Commun, PMID: 28240269.

[7] Pietzner, M., et al. “Mapping the proteo-genomic convergence of human diseases.” Science, PMID: 34648354.

[8] Garge, N. et al. “Identification of quantitative trait loci underlying proteome variation in human lymphoblastoid cells.” Mol Cell Proteomics, vol. 9, no. 7, 2010, pp. 1383–1399.

[9] Wu, L. et al. “Variation and genetic control of protein abundance in humans.” Nature, vol. 499, 2013, pp. 79–82.

[10] Hause, R. J. et al. “Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels.” Am J Hum Genet, vol. 95, no. 2, 2014, pp. 194–208.

[11] Petersen, A.-K. K. et al. “Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits.” Hum. Mol. Genet., 2010.

[12] Claussnitzer, M. et al. “Leveraging cross-species transcription factor binding site patterns: From diabetes risk loci to disease mechanisms.”Cell, vol. 156, no. 1-2, 2015, pp. 343–358.

[13] Suhre, K. and Gieger, C. “Genetic variation in metabolic phenotypes: study designs and applications.” Nat Rev Genet, vol. 13, no. 10, 2012, pp. 759–769.

[14] Plenge, R. M., Scolnick, E. M., and Altshuler, D. “Validating therapeutic targets through human genetics.” Nat Rev Drug Discov, vol. 12, no. 8, 2013, pp. 581–594.